Up-regulation of muscle UCP2 gene expression by a new β3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals

International Journal of Obesity

Volumn 24, Issue 2, 2000, Pages 156-163

  Berraondo, B ^a   Marti, A ^a   Duncan, J S ^b   Trayhurn, P ^b   Martinez J A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Leptin; Obesity; UCPs; 3 adrenergic agonists

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; FATTY ACID; LEPTIN; MESSENGER RNA; TRECADRINE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DIET; DOWN REGULATION; FEMALE; GASTROCNEMIUS MUSCLE; GENE EXPRESSION REGULATION; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WHITE ADIPOSE TISSUE;

ANIMALIA; CAFETERIA; RODENTIA;

EID: 0033965822     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801097     Document Type: Article

References (54)

1. 1 Stunkard AJ. Current view on obesity. Am J Med 1996; 100: 230-236.
2. 2 Rosembaum M, Leibel RL, Hirsch J. Obesity. New Engl J Med 1997; 337: 396-407.
3. 3 Weiser M, Frishman WH, Michaelson D, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37: 453-473.
4. 4 Lipworth BJ. Clinical pharmacology of β3-adrenoceptors. J Clin Pharmac 1996; 42: 219-230.
5. 5 Yen TT. β-Agonists as antiobesity, anti-diabetic and nutrient partitioning agents. Obes Res 1995; 3: 531-536.
6. 6 Strosberg AD. Structure and function of the β3-adrenergic receptor. Annu Rev Pharmac Toxicol 1997; 37: 421-450.
7. 7 Diez-Sampedro A, Milagro FI, Berraondo B, Zulet MA, Martínez JA. Effects of Trecadrine, a β3-adrenergic agonist, on intestinal absorption of D-galactose and disaccharidase activities in three physiopathological models. J Pharm Pharmac 1997; 49: 873-877.
8. 8 Berraondo B, Bonafonte A, Fernândez-Otero MP, Martinez JA. Effects on energy utilization of a β3-adrenergic agonist in rats fed on a cafeteria diet. Eating Weight Disord 1997; 2: 130-137.
9. 9 Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ, Int J Obes 1998; 22: 1145-1158.
10. 10 Arch JRS, Stock MJ, Trayhurn P. Leptin resistance in obese humans: Does it exist and what does it mean? Int J Obes 1998; 22: 1159-1163.
11. 11 Ghorbani M, Himms-Hagen J. Treatment with CL 316,243, a beta 3-adrenoceptor agonist, reduces serum leptin in rats with diet-or aging-associated obesity, but not in Zucker rats with genetic (fa/fa) obesity, Int J Obes 1998; 22: 63-65.
12. 12 Trayhurn P, Duncan JS, Rayner DV, Hardie LJ. Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the β3-adrenoceptor agonists BRL 351135 and ZD2079. Biochem Biophys Res Commun 1996; 228: 605-610.
13. 13 Fleury CH, Nerverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia. Nature Genet 1997; 15: 269-272.
14. 14 Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A, Seydoux J, Muzzin P, Giacobino JP. Uncoupling protein-3: A new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett 1997; 408: 39-42.
15. 15 Barrionuevo M, Milagro FI, Cenarruzabeitia E, Martinez JA. Potential anti-diabetic applications of a new molecule with affinity for β3-adrenoceptors. Life Sci 1996; 59: 141-146.
16. 16 Morbach AC, Brans YW. Determination of body composition in growing rats by total body electrical conductivity. J Pediatr Gaxtroenterol Nutr 1992; 14: 283-292.
17. 17 Hardie LJ, Rayner DV, Holmes S, Trayhurn P. Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Biochem Biophys Res Commun 1996; 223: 660-665.
18. 18 Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate phenolchloroform extraction. Anal Biochem 1987; 162: 156-159.
19. 19 Castelruiz Y, Larrea E, Boya P, Civeira MP, Prieto J. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatotogy 1999; 29: 1900-1904.
20. 20 Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor a gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-217.
21. 21 Larrea E, Beloqui O, Muñoz-Navas MA, Civeira MP, Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radical Biol Med 1998; 24: 1235-1241.
22. 22 Collins S, S+++urwit RS. Pharmacologic manipulation of ob expression in a dietary model of obesity. J Biol Chem 1996; 271: 9437-9440.
23. 23 Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984; 309: 163-165.
24. 24 Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD. Molecular characterization of the human β3-adrenergic receptor. Science 1989; 245: 1118-1121.
25. 25 Muzzin P, Revelli JP. Kühne F, Gocayne JD, McCombie WR, Venter JC, Giacabino JP, Fraser CM. An adipose tissue specific β-adrenergic receptor. Molecular cloning and downregulation in obesity. J Biol Chem 1991; 266: 24053-24058.
26. 26 Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ. Molecular characterization of the mouse β3-adrenergic receptor: Relationship with the atypical receptor of adipocytes. EMBO J 1991; 10: 3721-3727.
27. 27 Charon C, Dupoy F, Marie V, Bazin R. Effect of the β-adrenoceptor agonist BRL-35135 on development of obesity in suckling Zucker (fa/fa) rats. Am J Physiol 1995; 268: 1039-1045.
28. 28 Himms-Hagen J, Cui J, Danforth E, Taatjes DJ, Lang SS, Waters BL, Claus TH. Effect of CL-316,243, a thermogenic β3-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol 1994; 266: R1371-R 1382.
29. 29 Halloway BR, Howe R, Rao BS, Stribling D. ICI D7114: A novel selective adrenoceptor agonist of brown fat and thermogenesis. Am J Clin Nutr 1992; 55: 262-264.
30. 30 Hashimoto K, Nagao Y, Ida K, Takeda M, Murakami N, Kato K, Mizota M. Improvement of metabolic disorders and visceral fat obesity by the β3-adrenoceptor agonist (R *, R *)-(±)-methyl-4-[2-[2-hydroxy-2-3-chlorophenyl)ethylamino]-propyl]-phenoxyacetatehydrobromide (BRL 35135) in genetically obese rodents. Biochem Pharmac 1996; 52: 1529-1535.
31. 31 Umekawa T, Yoshida T, Sakane N, Saito M, Kumamoto K, Kondo M. Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific β3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima tatty rats: Induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol 1997; 136: 429-437.
32. 32 Giacobino JP. Role of the β3-adrenoceptor in the control of leptin expression. Horm Metab Res 1996; 28: 633-637.
33. 33 Senaris R, Garcia-Caballero T, Casabiell-X, Gallego R, Considine RV. Synthesis of leptin in human placenta. Endocrinology 1997; 138: 4501-4504.
34. 34 Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN, Moizo L, Lehy T, Guerre-Millo M, Le Marchand-Brustel Y, Lewin MJM. The stomach is a source of leptin. Nature 1998; 394: 790-797.
35. 35 Bray G, Bouchard C. Genetics of human obesity: Research directions. FASEB J 1997; 11: 937-945.
36. 36 Frühbeck G, Aguado G, Martínez JA. In vitro lipolytic effect of leptin on mouse adipocytes: Evidence for a possible autocrine/paracrine role of leptin. Biochem Biophys Res Commun 1997; 240: 590-594.
37. 37 Moinat M, Deng C, Muzzin P, Assimacopoulos-Jeannet F, Seydoux J, Dulloo AG, Giacobino JP. Modulation of obese gene expression in rat brown and white adipose tissues. FEBS Lett 1995; 373: 131-134.
38. 38 Yoshida T, Hayashi M, Monkawa T, Saruta T. Regulation of obese mRNA expression by hormonal factors in primary cultures of rat adipocytes. Eur J Endocrinol 1996; 135: 619-625.
39. 39 Berraondo B, Frühbeck G, Marti A, Femández-Otero MP, Martínez JA. The administration of aβ3-adrenergic agonist decreases leptin expression in a diet-induced obesity model. Proc Nutr Soc 1998; 57: 13A.
40. 40 Gong D, He Y, Karas M, Reitman M. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, β3-adrenergic agonists, and leptin. J Biol Chem 1997; 272: 24129-24132.
41. 41 Silva JE, Rabelo R. Regulation of the uncoupling protein gene expression. Eur J Endocrinol 1997; 136: 251-254.
42. 42 Klaus S, Munzberg H, Truloff C, Heldemaier G. Physiology of transgenic mice with brown fat ablation: Obesity is due to lowered body temperature. Am J Physiol 1998; 274: R287-R293.
43. 43 Florez-Duquet M, Horwitz BA, McDonald RB. Cellular proliferation and UCP content in brown adipose tissue of cold-exposed aging Fisher 344 rats. Am J Physiol 1998; 274: R194-R203.
44. 44 Bing C, Frankish HM, Pickavance L, Wang Q, Hopkins DF, Stock MJ, Williams G. Hyperphagia in cold-exposed rats is accompanied by decreased plasma leptin but unchanged hypothalamic NPY. Am J Physiol 1998; 274: R62-R68.
45. 45 Flier JS, Lowell BB. Obesity research springs a proton leak. Nature Genet 1997; 15: 223-224.
46. 46 Surwit RS, Wang S, Petro AN, Sanchis D, Raimbault S, Ricquier D, Collins S. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci USA 1998; 95: 4061-4965.
47. 47 Samec S, Seydoux J, Dulloo AG. Role of UCP homologues in skeletal muscles and brown adipose tissue: Mediators of thermogenesis or regulators of lipids as fuel substrate? FASEB J 1998; 12: 715-724.
48. 48 Ricquier D, Bouillaud F. Les protéines decouplantes mitochondriales. Med Sci 1998; 14: 889-897.
49. 49 Boss O, Samec, S, Dulloo A, Seydoux J, Muzzin P, Giacobino J. Tissue-dependent upregulation of rat uncoupling protein-2 expression in response to fasting or cold. FEBS Lett 1997; 412: 111-114.
50. 50 Simoneau JA, Rosenbaum M, Neverova M, Hirsch J, Leibel RL, Warden CH. Overexpression of muscle uncoupling protein-2 (UCP2) content is increased in human obesity associated with reduced muscle lipid utilization. Faseb J 1998; 12: 1739-1745.
51. 51 Kageyama H, Suga A, Kashiba M, Oka J, Osaka T, Kashiwa T, Hirano T, Nemoto K, Namba T. Increased uncoupling protein-2 and -3 gene expressions in skeletal muscle of STZ-induced diabetic rats. FEBS Lett 1998; 440: 450-453.
52. 52 Yoshitomi H, Yamazaki K, Abe S, Tanaka I. Differential regulation of mouse uncoupling proteins among BAT, WAT, and skeletal muscle in chronic β3-adrenergic receptor agonist treatment. Biochem Biophys Res Commun 1998; 253: 85-91.
53. 53 Emilsson V, Summers RJ, Hamilton S, Liu YL, Cawthorne MA. The effects of the β3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochem Biophys Res Commun 1998; 252: 450-454.
54. 54 Masaki T, Yoshimatsu H, Kakuma T, Hidaka S, Kurokawa M, Sakata T. Enhanced expression of uncoupling protein-2 gene in rat white adipose tissue and skeletal muscle following chronic treatment with thyroid hormone. FEBS Lett 1997; 418: 323-326.